Literature DB >> 25221649

Hydroxybenzothiophene Ketones Are Efficient Pre-mRNA Splicing Modulators Due to Dual Inhibition of Dyrk1A and Clk1/4.

Christian Schmitt1, Parisa Miralinaghi1, Marica Mariano1, Rolf W Hartmann2, Matthias Engel1.   

Abstract

Dysregulated usage of pre-mRNA splicing sites contributes to the progression of cancer, neurodegenerative diseases, and viral infections. Serine/arginine-rich (SR) proteins play major roles in the splice site recognition and are largely regulated by phosphorylation. This provides an option for the pharmacological correction of aberrant splicing by inhibiting the relevant kinases. Cdc2-like kinases (Clks) and dual specificity tyrosine phosphorylation-regulated kinases (Dyrks) were both reported to phosphorylate numerous SR proteins in vitro and in vivo. In this study, we describe the discovery of new selective dual Clk/Dyrk1A/1B inhibitors, which are able to modulate alternative pre-mRNA splicing of model gene transcripts in cells with submicromolar potencies. The optimization process yielded a dual Clk and Dyrk inhibitor with exceptionally high ligand efficiency. Our results suggested that dual inhibition of both Clk1 and Dyrk1A increased the efficacy of pre-mRNA splicing modulation.

Entities:  

Keywords:  Dual kinase inhibitor; alternative splicing modifiers; cdc2-like kinases; dual specificity tyrosine (Y) phosphorylation regulated kinases

Year:  2014        PMID: 25221649      PMCID: PMC4160750          DOI: 10.1021/ml500059y

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  27 in total

Review 1.  Function of alternative splicing.

Authors:  Olga Kelemen; Paolo Convertini; Zhaiyi Zhang; Yuan Wen; Manli Shen; Marina Falaleeva; Stefan Stamm
Journal:  Gene       Date:  2012-08-15       Impact factor: 3.688

2.  Regulation of alternative splicing of human tau exon 10 by phosphorylation of splicing factors.

Authors:  A M Hartmann; D Rujescu; T Giannakouros; E Nikolakaki; M Goedert; E M Mandelkow; Q S Gao; A Andreadis; S Stamm
Journal:  Mol Cell Neurosci       Date:  2001-07       Impact factor: 4.314

3.  Utilization of host SR protein kinases and RNA-splicing machinery during viral replication.

Authors:  Takeshi Fukuhara; Takamitsu Hosoya; Saki Shimizu; Kengo Sumi; Takako Oshiro; Yoshiyuki Yoshinaka; Masaaki Suzuki; Naoki Yamamoto; Leonore A Herzenberg; Leonard A Herzenberg; Masatoshi Hagiwara
Journal:  Proc Natl Acad Sci U S A       Date:  2006-07-13       Impact factor: 11.205

Review 4.  Regulation of splicing by SR proteins and SR protein-specific kinases.

Authors:  Zhihong Zhou; Xiang-Dong Fu
Journal:  Chromosoma       Date:  2013-03-24       Impact factor: 4.316

5.  Manipulation of alternative splicing by a newly developed inhibitor of Clks.

Authors:  Michiko Muraki; Bisei Ohkawara; Takamitsu Hosoya; Hiroshi Onogi; Jun Koizumi; Tomonobu Koizumi; Kengo Sumi; Jun-ichiro Yomoda; Michael V Murray; Hiroshi Kimura; Kiyoshi Furuichi; Hiroshi Shibuya; Adrian R Krainer; Masaaki Suzuki; Masatoshi Hagiwara
Journal:  J Biol Chem       Date:  2004-03-08       Impact factor: 5.157

6.  Chemical treatment enhances skipping of a mutated exon in the dystrophin gene.

Authors:  Atsushi Nishida; Naoyuki Kataoka; Yasuhiro Takeshima; Mariko Yagi; Hiroyuki Awano; Mitsunori Ota; Kyoko Itoh; Masatoshi Hagiwara; Masafumi Matsuo
Journal:  Nat Commun       Date:  2011       Impact factor: 14.919

7.  Specific CLK inhibitors from a novel chemotype for regulation of alternative splicing.

Authors:  Oleg Fedorov; Kilian Huber; Andreas Eisenreich; Panagis Filippakopoulos; Oliver King; Alex N Bullock; Damian Szklarczyk; Lars J Jensen; Doriano Fabbro; Jörg Trappe; Ursula Rauch; Franz Bracher; Stefan Knapp
Journal:  Chem Biol       Date:  2011-01-28

8.  Stress-responsive maturation of Clk1/4 pre-mRNAs promotes phosphorylation of SR splicing factor.

Authors:  Kensuke Ninomiya; Naoyuki Kataoka; Masatoshi Hagiwara
Journal:  J Cell Biol       Date:  2011-09-26       Impact factor: 10.539

9.  HIV-1 infection induces changes in expression of cellular splicing factors that regulate alternative viral splicing and virus production in macrophages.

Authors:  Dinushka Dowling; Somayeh Nasr-Esfahani; Chun H Tan; Kate O'Brien; Jane L Howard; David A Jans; Damian F j Purcell; C Martin Stoltzfus; Secondo Sonza
Journal:  Retrovirology       Date:  2008-02-04       Impact factor: 4.602

10.  Serine phosphorylation of SR proteins is required for their recruitment to sites of transcription in vivo.

Authors:  T Misteli; J F Cáceres; J Q Clement; A R Krainer; M F Wilkinson; D L Spector
Journal:  J Cell Biol       Date:  1998-10-19       Impact factor: 10.539

View more
  9 in total

1.  Design and synthesis of conformationally constraint Dyrk1A inhibitors by creating an intramolecular H-bond involving a benzothiazole core.

Authors:  Mohamed Salah; Mohammad Abdel-Halim; Matthias Engel
Journal:  Medchemcomm       Date:  2018-05-28       Impact factor: 3.597

2.  Selectivity Profiling and Biological Activity of Novel β-Carbolines as Potent and Selective DYRK1 Kinase Inhibitors.

Authors:  Katharina Rüben; Anne Wurzlbauer; Agnes Walte; Wolfgang Sippl; Franz Bracher; Walter Becker
Journal:  PLoS One       Date:  2015-07-20       Impact factor: 3.240

3.  10-iodo-11H-indolo[3,2-c]quinoline-6-carboxylic acids are selective inhibitors of DYRK1A.

Authors:  Hannes Falke; Apirat Chaikuad; Anja Becker; Nadège Loaëc; Olivier Lozach; Samira Abu Jhaisha; Walter Becker; Peter G Jones; Lutz Preu; Knut Baumann; Stefan Knapp; Laurent Meijer; Conrad Kunick
Journal:  J Med Chem       Date:  2015-03-23       Impact factor: 7.446

Review 4.  DYRK1A, a Dosage-Sensitive Gene Involved in Neurodevelopmental Disorders, Is a Target for Drug Development in Down Syndrome.

Authors:  Arnaud Duchon; Yann Herault
Journal:  Front Behav Neurosci       Date:  2016-06-03       Impact factor: 3.558

5.  Open PHACTS computational protocols for in silico target validation of cellular phenotypic screens: knowing the knowns.

Authors:  D Digles; B Zdrazil; J-M Neefs; H Van Vlijmen; C Herhaus; A Caracoti; J Brea; B Roibás; M I Loza; N Queralt-Rosinach; L I Furlong; A Gaulton; L Bartek; S Senger; C Chichester; O Engkvist; C T Evelo; N I Franklin; D Marren; G F Ecker; E Jacoby
Journal:  Medchemcomm       Date:  2016-05-11       Impact factor: 3.597

6.  Targeting CLK3 inhibits the progression of cholangiocarcinoma by reprogramming nucleotide metabolism.

Authors:  Qingxin Zhou; Meihua Lin; Xing Feng; Fei Ma; Yuekun Zhu; Xing Liu; Chao Qu; Hong Sui; Bei Sun; Anlong Zhu; Heng Zhang; He Huang; Zhi Gao; Yongxiang Zhao; Jiangyun Sun; Yuxian Bai; Junfei Jin; Xuehui Hong; Chang Zou; Zhiyong Zhang
Journal:  J Exp Med       Date:  2020-08-03       Impact factor: 14.307

7.  Synthesis of Bioactive 2-(Arylamino)thiazolo[5,4-f]-quinazolin-9-ones via the Hügershoff Reaction or Cu- Catalyzed Intramolecular C-S Bond Formation.

Authors:  Damien Hédou; Carole Dubouilh-Benard; Nadège Loaëc; Laurent Meijer; Corinne Fruit; Thierry Besson
Journal:  Molecules       Date:  2016-06-18       Impact factor: 4.411

Review 8.  Mutations in spliceosome genes and therapeutic opportunities in myeloid malignancies.

Authors:  Justin Taylor; Stanley C Lee
Journal:  Genes Chromosomes Cancer       Date:  2019-09-03       Impact factor: 5.006

9.  5-Methoxybenzothiophene-2-Carboxamides as Inhibitors of Clk1/4: Optimization of Selectivity and Cellular Potency.

Authors:  Ahmed K ElHady; Dalia S El-Gamil; Po-Jen Chen; Tsong-Long Hwang; Ashraf H Abadi; Mohammad Abdel-Halim; Matthias Engel
Journal:  Molecules       Date:  2021-02-13       Impact factor: 4.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.